8-K: bioAffinity Technologies Secures Key Canadian Patent for CyPath Lung Diagnostic

bioAffinity Technologies announced the allowance of a Canadian patent for its CyPath Lung diagnostic, strengthening its intellectual property and opening market expansion opportunities in Canada.

Summary

• bioAffinity Technologies, Inc. received notification of allowance from the Canadian Patent Office for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry.
• The newly allowed Canadian patent, titled 'System and Method for Determining Lung Health' (Patent No. 3,136,245), protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells.
• This patent strengthens the international protection of the company's diagnostic platform that powers its flagship test, CyPath Lung.
• CyPath Lung is a noninvasive test for early-stage lung cancer, with clinical study results demonstrating 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules less than 20 millimeters.
• Lung cancer is the leading cause of cancer death in Canada, with approximately 31,000 Canadians diagnosed and 20,700 deaths in 2024, where 50% of cases are diagnosed at Stage IV with a five-year survival rate of about 19%.

Sentiment

Score: 8

Explanation: The allowance of a key patent in a significant market like Canada for a diagnostic product is a strong positive for a biotechnology company, enhancing its intellectual property and market potential. The filing contains no negative financial or operational news.

Positives

• Allowance of a new Canadian patent strengthens the international protection of the company's diagnostic platform.
• The patent expands the global footprint of the intellectual property portfolio, validating the science behind CyPath Lung.
• The patent enables market expansion into Canada, a region where lung cancer is a leading cause of cancer deaths and early detection is critical.
• CyPath Lung has demonstrated high performance with 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.

Risks

• The benefits to be derived from the patent are subject to various risks and uncertainties.
• The company's ability to safeguard its intellectual property may be impacted by unforeseen challenges.
• The ability to successfully market CyPath Lung in Canada is subject to various risks and uncertainties.
• Actual results could differ materially from current expectations and assumptions due to factors discussed in the company's Annual Report on Form 10-K and subsequent SEC filings.

Future Outlook

The company believes the patent will provide benefits, enable it to safeguard its intellectual property, and facilitate the marketing of CyPath Lung in Canada. These forward-looking statements are based on current estimates and assumptions.

Management Comments

• "This Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives." Maria Zannes, President and CEO of bioAffinity Technologies.
• "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science." Maria Zannes, President and CEO of bioAffinity Technologies.

Industry Context

The allowance of this patent is significant given that lung cancer is the leading cause of cancer death in Canada, with a high percentage of cases diagnosed at late stages and a low five-year survival rate. A noninvasive, accurate early detection test like CyPath Lung could address a critical unmet medical need in the Canadian market, potentially improving patient outcomes and survival rates.

Comparison to Industry Standards

• The filing highlights that 50% of all lung cancer cases in Canada are diagnosed late at Stage IV, with an overall five-year survival rate of about 19%. CyPath Lung's ability to detect lung cancer at its earliest stages (92% sensitivity, 87% specificity, 88% accuracy) positions it as a valuable tool to potentially improve these statistics, especially when compared to the challenges of late-stage diagnosis in the Canadian healthcare system.

Stakeholder Impact

• Shareholders: Enhanced long-term shareholder value through intellectual property protection and market expansion.
• Patients: Potential for improved outcomes and increased survival rates through earlier detection of lung cancer in Canada.
• Healthcare Providers: Provision of a noninvasive, accurate diagnostic tool for early-stage lung cancer.

Next Steps

• The company intends to market CyPath Lung in Canada, leveraging the newly granted patent.
• Continued execution toward building long-term shareholder value through innovation and protection of unique assets.

Key Dates

Recommendation

The allowance of a significant patent in a key market like Canada for a diagnostic test addressing a critical unmet medical need (early lung cancer detection) is a substantial positive catalyst. This strengthens the company's intellectual property, validates its technology, and opens a new revenue stream, making the stock highly attractive for long-term growth.

Keywords

Biotechnology, Lung Cancer, Diagnostics, Patent, Canada, CyPath Lung, Flow Cytometry, Early Cancer Detection, Intellectual Property, Healthcare